Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia

被引:80
作者
Harvey, PD
Meltzer, H
Simpson, GM
Potkin, SG
Loebel, A
Siu, C
Romano, SJ
机构
[1] CUNY, Mt Sinai Med Ctr, New York, NY 10029 USA
[2] Hosp Psychiat, Vanderbilt Med Ctr, Nashville, TN 37212 USA
[3] Univ So Calif, LAC Med Ctr, Dept Psychiat, Los Angeles, CA USA
[4] Univ Calif Irvine, Neuropsychiat Ctr, Irvine, CA 92868 USA
[5] Pfizer Inc, Pfizer Pharmaceut Grp, New York, NY 10017 USA
关键词
schizophrenia; cognition; ziprasidone; atypical antipsychotics; executive functioning; vigilance; attention; verbal fluency;
D O I
10.1016/j.schres.2003.07.009
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To assess changes in cognitive function in stable outpatients with schizophrenia switched to ziprasidone from conventional antipsychotics (n = 108), olanzapine (n = 104), or risperidone (n = 58) because of suboptimal efficacy or poor tolerability. Methods: In three separate 6-week trials, patients received ziprasidone 40 mg b.i.d. for 2 days, followed by 20-80 mg b.i.d. for the next 40 days. Before switching, and at endpoint, patients were evaluated with tests of working and secondary verbal memory, vigilance, visuomotor speed, verbal fluency, and executive functioning. Principal components factor analysis was performed to test for clustering of cognitive variables. Results: Significant improvements were seen at endpoint in secondary verbal memory (in all three groups), vigilance (in patients switched from conventional antipsychotics or risperidone), executive function (in patients switched from conventional antipsychotics or risperidone), and verbal fluency. Factor analysis on baseline scores suggested reduction of the cognitive variables to three factors: verbal skills, attention and short-term memory, and executive functioning. Analysis of z-transfonned mean change in factor scores showed significant improvement in verbal skills and global score following the switch from conventional antipsychotics, olanzapine, or risperidone. Conclusions: Patients requiring a change in antipsychotic therapy may exhibit cognitive improvement following a switch to ziprasidone. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:101 / 113
页数:13
相关论文
共 46 条
[1]   COGNITIVE-FUNCTIONING AND POSITIVE AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA [J].
ADDINGTON, J ;
ADDINGTON, D ;
MATICKATYNDALE, E .
SCHIZOPHRENIA RESEARCH, 1991, 5 (02) :123-134
[2]   A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study [J].
Arato, M ;
O'Connor, R ;
Meltzer, HY .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (05) :207-215
[3]   Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder [J].
Bilder, RM ;
Goldman, RS ;
Volavka, J ;
Czobor, P ;
Hoptman, M ;
Sheitman, B ;
Lindenmayer, JP ;
Citrome, L ;
McEvoy, J ;
Kunz, M ;
Chakos, M ;
Cooper, TB ;
Horowitz, TL ;
Lieberman, JA .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (06) :1018-1028
[4]   Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates [J].
Bilder, RM ;
Goldman, RS ;
Robinson, D ;
Reiter, G ;
Bell, L ;
Bates, JA ;
Pappadopulos, E ;
Willson, DF ;
Alvir, JMJ ;
Woerner, MG ;
Geisler, S ;
Kane, JM ;
Lieberman, JA .
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (04) :549-559
[5]  
Blyler C.R., 2000, COGNITION SCHIZOPHRE, P241
[6]   NEUROLEPTIC DRUG EFFECTS ON COGNITIVE FUNCTION IN SCHIZOPHRENIA [J].
CLEGHORN, JM ;
KAPLAN, RD ;
SZECHTMAN, B ;
SZECHTMAN, H ;
BROWN, GM .
SCHIZOPHRENIA RESEARCH, 1990, 3 (03) :211-219
[7]   Cognitive and behavioral precursors of schizophrenia [J].
Cornblatt, B ;
Obuchowski, M ;
Roberts, S ;
Pollack, S ;
Erlenmeyer-Kimling, L .
DEVELOPMENT AND PSYCHOPATHOLOGY, 1999, 11 (03) :487-508
[8]   THE CONTINUOUS PERFORMANCE-TEST, IDENTICAL PAIRS VERSION .2. CONTRASTING ATTENTIONAL PROFILES IN SCHIZOPHRENIC AND DEPRESSED-PATIENTS [J].
CORNBLATT, BA ;
LENZENWEGER, MF ;
ERLENMEYERKIMLING, L .
PSYCHIATRY RESEARCH, 1989, 29 (01) :65-85
[9]   Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial [J].
Daniel, DG ;
Zimbroff, DL ;
Potkin, SG ;
Reeves, KR ;
Harrigan, EP ;
Lakshminarayanan, M .
NEUROPSYCHOPHARMACOLOGY, 1999, 20 (05) :491-505
[10]  
DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474